Structural variability of CD44v molecules and reliability of immunodetection of CD44 isoforms using mAbs specific for CD44 variant exon products.

[1]  I. Stamenkovic,et al.  Glycosylation Provides Both Stimulatory and Inhibitory Effects on Cell Surface and Soluble CD44 Binding to Hyaluronan , 1998, The Journal of cell biology.

[2]  I. Stamenkovic,et al.  Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan , 1996, The Journal of cell biology.

[3]  K. Bennett,et al.  Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons , 1995, The Journal of cell biology.

[4]  A. Perschl,et al.  Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation , 1995, The Journal of experimental medicine.

[5]  K. Bennett,et al.  Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. , 1995, Journal of cell science.

[6]  P. Kincade,et al.  Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. , 1994, Journal of immunology.

[7]  I. Stamenkovic,et al.  Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development , 1994, The Journal of experimental medicine.

[8]  A. Bartolazzi,et al.  Integrin expression in cutaneous malignant melanoma: Association of the α3/β1 heterodimer with tumor progression , 1993 .

[9]  P. Herrlich,et al.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44 , 1993, The Journal of experimental medicine.

[10]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Tarin,et al.  Significance of CD44 gene products for cancer diagnosis and disease evaluation , 1992, The Lancet.

[12]  I. Stamenkovic,et al.  Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein , 1992, The Journal of experimental medicine.

[13]  P. Herrlich,et al.  Participation in normal immune responses of a metastasis-inducing splice variant of CD44. , 1992, Science.

[14]  J. Bell,et al.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. , 1992, The Journal of biological chemistry.

[15]  D. Anstee,et al.  New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. , 1991, Immunology.

[16]  Martin Hofmann,et al.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells , 1991, Cell.

[17]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[18]  S. Ho,et al.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction. , 1989, Gene.

[19]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[20]  U. Günthert,et al.  CD44 in malignant disorders. , 1996, Current topics in microbiology and immunology.